Log in

NASDAQ:MTEMMolecular Templates Stock Price, Forecast & News

+0.03 (+0.25 %)
(As of 08/13/2020 04:00 PM ET)
Today's Range
Now: $12.02
50-Day Range
MA: $12.61
52-Week Range
Now: $12.02
Volume285,300 shs
Average Volume350,619 shs
Market Capitalization$600.03 million
P/E RatioN/A
Dividend YieldN/A
Molecular Templates, Inc., a clinical stage oncology company, focuses on the discovery and development of biologic therapeutics for the treatment of cancer and other diseases. The company primarily develops a pipeline of engineered toxin bodies. Its lead drug candidate is MT-3724 that is in a Phase II clinical trial for the treatment of relapsed/refractory diffuse large B-cell lymphoma; and Phase II clinical trial for treating non-Hodgkin's lymphoma. The company also develops MT-4019, engineered toxin body targeting CD38; and TAK-169 targeting CD38. It has an agreement with Takeda Pharmaceutical Company Limited to develop CD38-targeted engineered toxin bodies for the treatment of patients with diseases, such as multiple myeloma. Molecular Templates, Inc. is headquartered in Austin, Texas.
Read More
Molecular Templates logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 2.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.62 out of 5 stars

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:MTEM



Sales & Book Value

Annual Sales$22.27 million
Book Value$2.79 per share


Net Income$-69,420,000.00
Net Margins-514.48%


Market Cap$600.03 million
Next Earnings Date11/10/2020 (Estimated)
OptionableNot Optionable
+0.03 (+0.25 %)
(As of 08/13/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive MTEM News and Ratings via Email

Sign-up to receive the latest news and ratings for MTEM and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Molecular Templates (NASDAQ:MTEM) Frequently Asked Questions

How has Molecular Templates' stock price been impacted by COVID-19?

Molecular Templates' stock was trading at $13.22 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, MTEM stock has decreased by 9.1% and is now trading at $12.02.
View which stocks have been most impacted by COVID-19

Do Wall Street analysts recommend investors buy shares of Molecular Templates?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Molecular Templates in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Molecular Templates

When is Molecular Templates' next earnings date?

Molecular Templates is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Molecular Templates

How were Molecular Templates' earnings last quarter?

Molecular Templates Inc (NASDAQ:MTEM) issued its earnings results on Thursday, August, 6th. The biotechnology company reported ($0.65) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by $0.28. The biotechnology company earned $6.91 million during the quarter, compared to the consensus estimate of $5.04 million. Molecular Templates had a negative net margin of 514.48% and a negative return on equity of 105.07%.
View Molecular Templates' earnings history

When did Molecular Templates' stock split? How did Molecular Templates' stock split work?

Molecular Templates's stock reverse split on the morning of Wednesday, August 2nd 2017. The 1-11 reverse split was announced on Tuesday, August 1st 2017. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, August 1st 2017. An investor that had 100 shares of Molecular Templates stock prior to the reverse split would have 9 shares after the split.

What price target have analysts set for MTEM?

4 brokers have issued 12 month price targets for Molecular Templates' shares. Their forecasts range from $19.00 to $22.00. On average, they expect Molecular Templates' stock price to reach $21.00 in the next twelve months. This suggests a possible upside of 74.7% from the stock's current price.
View analysts' price targets for Molecular Templates

Has Molecular Templates been receiving favorable news coverage?

News coverage about MTEM stock has trended positive on Friday, according to InfoTrie. The research group identifies positive and negative media coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores closest to five being the most favorable. Molecular Templates earned a coverage optimism score of 2.7 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an effect on the company's share price in the near term.
View the latest news about Molecular Templates

Are investors shorting Molecular Templates?

Molecular Templates saw a increase in short interest during the month of June. As of June 30th, there was short interest totaling 1,600,000 shares, an increase of 40.4% from the June 15th total of 1,140,000 shares. Based on an average trading volume of 353,200 shares, the short-interest ratio is currently 4.5 days. Currently, 5.3% of the company's shares are sold short.
View Molecular Templates' Short Interest

Who are some of Molecular Templates' key competitors?

What other stocks do shareholders of Molecular Templates own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Molecular Templates investors own include ZIOPHARM Oncology (ZIOP), Novavax (NVAX), Gilead Sciences (GILD), Synergy Pharmaceuticals (SGYP), TG Therapeutics (TGTX), Corbus Pharmaceuticals (CRBP), CEL-SCI (CVM), Soleno Therapeutics (SLNO), SLS International (SLS) and Amarin (AMRN).

Who are Molecular Templates' key executives?

Molecular Templates' management team includes the following people:
  • Dr. Eric E. Poma, CEO, Chief Scientific Officer & Director (Age 47)
  • Ms. Jason S Kim, Pres & COO (Age 44)
  • Mr. Adam D. Cutler B.A., Chief Financial Officer (Age 44)
  • Mr. Kurt Elster, Exec. VP of Corp. Devel. (Age 52)
  • Dr. Jack Higgins Ph.D., Exec. VP of Operations & Head of Manufacturing (Age 39)

What is Molecular Templates' stock symbol?

Molecular Templates trades on the NASDAQ under the ticker symbol "MTEM."

Who are Molecular Templates' major shareholders?

Molecular Templates' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Bellevue Group AG (6.97%), Federated Hermes Inc. (0.23%), FMR LLC (0.22%), Bank of New York Mellon Corp (0.22%), Monashee Investment Management LLC (0.20%) and Public Employees Retirement Association of Colorado (0.15%). Company insiders that own Molecular Templates stock include Associates LLC Cdk, David Hirsch, Kevin M Lalande, Longitude Capital Partners Iii and Scott D Morenstein.
View institutional ownership trends for Molecular Templates

Which major investors are selling Molecular Templates stock?

MTEM stock was sold by a variety of institutional investors in the last quarter, including FMR LLC, Monashee Investment Management LLC, EAM Investors LLC, Russell Investments Group Ltd., Hancock Whitney Corp, Dupont Capital Management Corp, Strs Ohio, and ClariVest Asset Management LLC.
View insider buying and selling activity for Molecular Templates

Which major investors are buying Molecular Templates stock?

MTEM stock was acquired by a variety of institutional investors in the last quarter, including Bellevue Group AG, Public Employees Retirement Association of Colorado, Alps Advisors Inc., Federated Hermes Inc., Algert Global LLC, Swiss National Bank, Athanor Capital LP, and Bank of New York Mellon Corp. Company insiders that have bought Molecular Templates stock in the last two years include Associates LLC Cdk, David Hirsch, Longitude Capital Partners Iii, and Scott D Morenstein.
View insider buying and selling activity for Molecular Templates

How do I buy shares of Molecular Templates?

Shares of MTEM can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Molecular Templates' stock price today?

One share of MTEM stock can currently be purchased for approximately $12.02.

How big of a company is Molecular Templates?

Molecular Templates has a market capitalization of $600.03 million and generates $22.27 million in revenue each year. The biotechnology company earns $-69,420,000.00 in net income (profit) each year or ($1.26) on an earnings per share basis. Molecular Templates employs 68 workers across the globe.

What is Molecular Templates' official website?

The official website for Molecular Templates is www.mtem.com.

How can I contact Molecular Templates?

Molecular Templates' mailing address is 9301 AMBERGLEN BLVD. SUITE 100, AUSTIN TX, 78729. The biotechnology company can be reached via phone at 512-869-1555 or via email at [email protected]

This page was last updated on 8/14/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.